ArticleNeuroscience letters2016
Advanced age negatively impacts survival in an experimental brain tumor model.
Article in Neuroscience letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Neuro-oncology · 2025Review
- Antitumoral Activity of Cecropia Pachystachya Leaves Extract in Vitro and in Vivo Model of Rat Glioma: Brain and Blood Effects.Molecular neurobiology · 2024Article
- Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Article
- Sex-Specific Differences in Glioblastoma.Cells · 2021Review
- Article
- Review
- Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.Frontiers in immunology · 2021Review
- Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Clinical Significance of Various Classification Standards of Age Groups in Predicting Survival of Patients with Glioblastoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.Frontiers in immunology · 2020Review
- The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.Frontiers in pharmacology · 2019Article
- Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by GargOncoimmunology · 2019Article
- Impact of Age on Disease Progression and Microenvironment in Oral Cancer.Journal of dental research · 2018Article
- IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- IDO1 in cancer: a Gemini of immune checkpoints.Cellular & molecular immunology · 2018Review
- Management of glioblastoma in elderly patients.Journal of the neurological sciences · 2017Review
- Glioblastoma as an age-related neurological disorder in adults.Neuro-oncology advancesReview
- Age-dependent glioma progression and functional decline in a syngeneic murine model: Host vulnerabilities and opportunities for targeted intervention.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with an average age of 64 years at the time of diagnosis. To study GBM, a number of mouse brain tumor models have been utilized. In these animal models, subjects tend to range from 6 to 12 weeks of age, which is analogous to that of a human teenager. Here, we examined the impact of age on host immunity and the gene expression associated with immune evasion in immunocompetent mice engrafted with syngeneic intracranial GL261. The data indicate that, in mice with brain tumors, youth conveys an advantage to survival. While age did not affect the tumor-infiltrating T cell phenotype or quantity, we discovered that old mice express higher levels of the immunoevasion enzyme, IDO1, which was decreased by the presence of brain tumor. Interestingly, other genes associated with promoting immunosuppression including CTLA-4, PD-L1 and FoxP3, were unaffected by age. These data highlight the possibility that IDO1 contributes to faster GBM outgrowth with advanced age, providing rationale for future investigation into immunotherapeutic targeting in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.